PT2508521E - Dimaleato de um composto de aminocrotonilo e processo para a sua preparação - Google Patents

Dimaleato de um composto de aminocrotonilo e processo para a sua preparação Download PDF

Info

Publication number: PT2508521E
Authority: PT; Portugal
Prior art keywords: dimaleat; production; compound; amino; amino crotonyl
Prior art date: 2003-10-17

Application number

PT121556625T

Other languages

English (en)

Inventor

Rall Werner

Kulinna Christian

Schnaubelt Juergen

Sieger Peter

Soyka Rainer

Original Assignee

Boehringer Ingelheim Int

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-17

Filing date

2004-10-12

Publication date

2016-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34428508&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2508521(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-12 Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Int

2016-03-31 Publication of PT2508521E publication Critical patent/PT2508521E/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT121556625T 2003-10-17 2004-10-12 Dimaleato de um composto de aminocrotonilo e processo para a sua preparação PT2508521E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10349113A DE10349113A1 (de)	2003-10-17	2003-10-17	Verfahren zur Herstellung von Aminocrotonylverbindungen

Publications (1)

Publication Number	Publication Date
PT2508521E true PT2508521E (pt)	2016-03-31

Family

ID=34428508

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT47659271T PT1678165E (pt)	2003-10-17	2004-10-12	Processo para a preparação de compostos de aminocrotonilo
PT121556625T PT2508521E (pt)	2003-10-17	2004-10-12	Dimaleato de um composto de aminocrotonilo e processo para a sua preparação

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT47659271T PT1678165E (pt)	2003-10-17	2004-10-12	Processo para a preparação de compostos de aminocrotonilo

Country Status (35)

Country	Link
US (2)	US20050085495A1 (pt)
EP (2)	EP2508521B2 (pt)
JP (2)	JP4594317B2 (pt)
KR (2)	KR101282812B1 (pt)
CN (2)	CN101402631A (pt)
AR (1)	AR046118A1 (pt)
AU (2)	AU2004281938B2 (pt)
BR (2)	BRPI0415424B8 (pt)
CA (2)	CA2759063C (pt)
CY (2)	CY1114866T1 (pt)
DE (1)	DE10349113A1 (pt)
DK (2)	DK1678165T3 (pt)
EA (1)	EA016624B1 (pt)
EC (1)	ECSP066509A (pt)
ES (2)	ES2440466T3 (pt)
HK (1)	HK1095817A1 (pt)
HR (2)	HRP20160246T4 (pt)
HU (1)	HUE028254T2 (pt)
IL (2)	IL174951A (pt)
ME (1)	ME00341B (pt)
MX (2)	MXPA06004076A (pt)
MY (2)	MY155425A (pt)
NO (2)	NO333971B1 (pt)
NZ (2)	NZ583049A (pt)
PE (2)	PE20050965A1 (pt)
PL (2)	PL2508521T5 (pt)
PT (2)	PT1678165E (pt)
RS (3)	RS60563B1 (pt)
SG (1)	SG139743A1 (pt)
SI (2)	SI2508521T2 (pt)
TW (2)	TWI348468B (pt)
UA (2)	UA91006C2 (pt)
UY (2)	UY28559A1 (pt)
WO (1)	WO2005037824A2 (pt)
ZA (1)	ZA200602234B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK287010B6 (sk)	1999-06-21	2009-09-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) *	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
KR100832594B1 (ko) *	2005-11-08	2008-05-27	한미약품 주식회사	다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
PL1948180T3 (pl)	2005-11-11	2013-09-30	Boehringer Ingelheim Int	Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
WO2007054550A1 (en) *	2005-11-11	2007-05-18	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
CA2639936C (en) *	2006-01-26	2014-06-17	Boehringer Ingelheim International Gmbh	Process for preparing aminocrotonylamino-substituted quinazoline derivatives
BRPI0717586A2 (pt)	2006-09-18	2013-10-29	Boehringer Ingelheim Int	Método para tratar câncer apresentando mutações do egfr
PE20100252A1 (es) *	2008-06-06	2010-04-12	Boehringer Ingelheim Int	Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
WO2010081817A1 (en)	2009-01-14	2010-07-22	Boehringer Ingelheim International Gmbh	Method for treating colorectal cancer
CN105541836A (zh)	2009-03-11	2016-05-04	奥克兰联合服务有限公司	激酶抑制剂的前药形式及其在治疗中的用途
WO2010130757A1 (en)	2009-05-14	2010-11-18	Boehringer Ingelheim International Gmbh	New combination therapy in treatment of oncological and fibrotic diseases
CA2804190A1 (en) *	2009-07-02	2011-01-06	Newgen Therapeutics, Inc.	Phosphorus containing quinazoline compounds and methods of use
WO2011003853A2 (en)	2009-07-06	2011-01-13	Boehringer Ingelheim International Gmbh	Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
JP2013512882A (ja)	2009-12-07	2013-04-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
US20120107304A1 (en) *	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
PL2608792T3 (pl)	2010-08-26	2018-03-30	Boehringer Ingelheim International Gmbh	Sposoby podawania inhibitora EGFR
JP5808818B2 (ja) *	2010-11-25	2015-11-10	ラツィオファーム・ゲーエムベーハー	アファチニブの新規塩及び多形形態
KR20210043016A (ko)	2011-03-04	2021-04-20	뉴젠 세러퓨틱스 인코포레이티드	알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102731485B (zh) *	2011-04-02	2016-06-15	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
CN102918029B (zh)	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN102838590B (zh) *	2011-06-21	2014-07-09	苏州迈泰生物技术有限公司	氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
US20170079444A1 (en) *	2011-09-22	2017-03-23	Future Foam, Inc.	Enhanced washable mattress topper
US20150232457A1 (en)	2011-10-06	2015-08-20	Ratiopharm Gmbh	Crystalline forms of afatinib di-maleate
CN103073539B (zh) *	2011-10-26	2016-05-11	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
EP2875020B1 (en)	2012-07-19	2017-09-06	Boehringer Ingelheim International GmbH	Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
JP2016511754A (ja)	2013-02-01	2016-04-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	放射性標識キナゾリン誘導体
WO2014180271A1 (zh) *	2013-05-10	2014-11-13	苏州明锐医药科技有限公司	阿法替尼及其中间体的制备方法
CN103254156B (zh) *	2013-05-10	2015-08-26	苏州明锐医药科技有限公司	阿法替尼中间体的制备方法
CN103242303B (zh) *	2013-05-16	2015-03-25	苏州明锐医药科技有限公司	阿法替尼的制备方法
CN103288808B (zh) *	2013-05-16	2015-11-11	苏州明锐医药科技有限公司	一种阿法替尼的制备方法
CN104540820B (zh) *	2013-07-16	2016-12-21	杭州普晒医药科技有限公司	阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
CN104513229A (zh) *	2013-09-28	2015-04-15	正大天晴药业集团股份有限公司	喹唑啉衍生物及其制备方法
CN104710413B (zh) *	2013-12-16	2019-05-03	江苏豪森药业集团有限公司	二马来酸阿法替尼的制备方法
CN104744445A (zh) *	2013-12-30	2015-07-01	广东东阳光药业有限公司	一种酪氨酸激酶抑制剂的晶型
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015103456A1 (en) *	2014-01-02	2015-07-09	Teva Pharmaceuticals International Gmbh	Crystalline forms of afatinib di-maleate
CN104803992A (zh) *	2014-01-25	2015-07-29	广东东阳光药业有限公司	阿法替尼盐的晶型
WO2016001844A1 (en) *	2014-06-30	2016-01-07	Sun Pharmaceutical Industries Limited	Amorphous form of afatinib dimaleate
CN105315263B (zh) *	2014-07-30	2018-11-27	正大天晴药业集团股份有限公司	阿法替尼中间体的合成方法
WO2016027243A1 (en) *	2014-08-21	2016-02-25	Dr. Reddy’S Laboratories Limited	Novel solid state forms of afatinib dimaleate
WO2016051380A1 (en) *	2014-10-01	2016-04-07	Sun Pharmaceutical Industries Limited	Crystalline form of afatinib dimaleate
CN105534920B (zh) *	2014-10-29	2020-07-10	江苏豪森药业集团有限公司	一种药物组合物及其制备方法
CN104402872B (zh) *	2014-11-14	2016-08-24	广东东阳光药业有限公司	一种结晶除杂方法
CN104447713B (zh) *	2014-11-18	2019-03-29	江苏奥赛康药业股份有限公司	阿法替尼化合物的制备方法
EP3023421A1 (en)	2014-11-21	2016-05-25	Sandoz Ag	Crystalline forms of afatinib dimaleate
CN104529800B (zh) *	2014-12-08	2017-01-25	重庆威鹏药业有限公司	反式‑4‑二甲基氨基巴豆酸及盐的制备方法
CN105801567A (zh) *	2014-12-31	2016-07-27	徐州万邦金桥制药有限公司	一种双马来酸阿法替尼的纯化方法
CN105801568B (zh) *	2015-01-15	2019-07-30	杭州普晒医药科技有限公司	阿法替尼一马来酸盐晶型及其制备方法和药物组合物
CN107406430B (zh)	2015-03-20	2019-04-26	正大天晴药业集团股份有限公司	喹唑啉衍生物的盐及其制备方法
CA2982423C (en)	2015-04-17	2024-01-16	Hetero Labs Ltd	Polymorphs and process for the preparation of quinazolinyl derivatives
CN105859641B (zh) *	2015-05-05	2018-11-16	杭州华东医药集团新药研究院有限公司	喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN104892584B (zh) *	2015-05-27	2018-03-23	重庆泰濠制药有限公司	一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
EP3307737A2 (en)	2015-06-12	2018-04-18	Fresenius Kabi Oncology Ltd	Polymorphic forms of afatinib free base and afatinib dimaleate
CN104926800A (zh) *	2015-06-26	2015-09-23	河北神威药业有限公司	一种阿法替尼二马来酸盐的结晶形式及其制备方法
CN105175331B (zh) *	2015-08-14	2019-04-26	江苏苏中药业集团股份有限公司	一种egfr类分子靶向抗肿瘤药物的制备方法
KR20180066039A (ko)	2015-08-21	2018-06-18	프레세니어스 카비 온콜로지 리미티드	아파티닙을 포함하는 약학적 조성물
WO2017093789A1 (en) *	2015-12-03	2017-06-08	Mylan Laboratories Ltd.	Polymorphic forms of afatinib dimaleate
CN106831733B (zh) *	2015-12-07	2021-05-11	海南先声药业有限公司	阿法替尼顺式异构体的制备方法与应用
CN106866641A (zh) *	2015-12-11	2017-06-20	河北神威药业有限公司	一种阿法替尼的精制方法
JP6674027B2 (ja) *	2015-12-25	2020-04-01	シュアンチューファーマカンパニー，リミティド	キナゾリン誘導体の結晶及びその調製方法
CN106916147A (zh) *	2015-12-25	2017-07-04	中美华世通生物医药科技（武汉）有限公司	化合物及其制备方法和用途
CN105669658B (zh) *	2016-04-05	2018-06-29	北京民康百草医药科技有限公司	一种阿法替尼的精制方法
CN107488194B (zh) *	2016-06-10	2021-07-30	山东新时代药业有限公司	一种阿法替尼中间体及其制备方法
CN107488153B (zh) *	2016-06-10	2020-06-23	山东新时代药业有限公司	一种阿法替尼中间体化合物
CN107488171B (zh) *	2016-06-10	2020-08-28	山东新时代药业有限公司	一种阿法替尼制备方法
CN107488172B (zh) *	2016-06-10	2020-06-12	山东新时代药业有限公司	一种阿法替尼的制备方法
CN106243092B (zh) *	2016-07-28	2019-02-15	南京臣功制药股份有限公司	一种高选择性制备马来酸阿法替尼的方法
MX2019005834A (es)	2016-11-17	2019-10-14	Univ Texas	Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2.
TWI808958B (zh)	2017-01-25	2023-07-21	美商特普醫葯公司	涉及二芳基巨環化合物之組合療法
JP2020513006A (ja)	2017-04-06	2020-04-30	ジョンソン、マッセイ、パブリック、リミテッド、カンパニーＪｏｈｎｓｏｎＭａｔｔｈｅｙＰｕｂｌｉｃＬｉｍｉｔｅｄＣｏｍｐａｎｙ	アファチニブジマレアートの新規形態
CN108358900A (zh) *	2018-03-30	2018-08-03	东北制药集团股份有限公司	一种阿法替尼及其马来酸盐的制备方法
KR20190141607A (ko)	2018-06-14	2019-12-24	주식회사 에이티파머	알로페론을 포함하는 췌장암 치료용 조성물 및 치료 보조제
KR102257913B1 (ko)	2018-07-17	2021-05-28	주식회사 에이티파머	알로페론을 포함하는 폐섬유증 치료용 조성물
CN109824657A (zh) *	2019-03-26	2019-05-31	石药集团中奇制药技术（石家庄）有限公司	一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110563710B (zh) *	2019-09-21	2020-05-19	广东安诺药业股份有限公司	一种马来酸阿法替尼的制备方法
CN110590754A (zh) *	2019-09-21	2019-12-20	广东安诺药业股份有限公司	一种马来酸阿法替尼中间体的制备方法
CN113121512B (zh) *	2019-12-30	2022-11-04	江苏晶立信医药科技有限公司	一种喹唑啉基丁烯酰胺类化合物的制备方法
KR20210106158A (ko)	2020-02-20	2021-08-30	서울대학교산학협력단	알로페론을 포함하는 항암 치료 보조제
KR20210106157A (ko)	2020-02-20	2021-08-30	서울대학교산학협력단	알로페론을 포함하는 난소암 치료용 조성물 및 치료 보조제
CN114315808A (zh) *	2020-10-10	2022-04-12	西安新通药物研究有限公司	一种高收率马来酸阿法替尼的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8618846D0 (en)	1986-08-01	1986-09-10	Smithkline Beckman Corp	Chemical process
JPS6442472A (en)	1987-08-10	1989-02-14	Kanebo Ltd	Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
GB9005014D0 (en) *	1990-03-06	1990-05-02	Janssen Pharmaceutica Nv	N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
RU2043352C1 (ru) *	1991-07-01	1995-09-10	Пермский фармацевтический институт	2-пропил-3- (5-нитрофурфулиден)амино- 4(3н)-хиназолинон, проявляющий противостафилококковую и анальгетическую активность
GB9300059D0 (en)	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
EP0817775B1 (en)	1995-03-30	2001-09-12	Pfizer Inc.	Quinazoline derivatives
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
CZ1598A3 (cs)	1995-07-06	1998-04-15	Novartis Ag	Pyrrolopyrimidiny a způsoby jejich přípravy
DK0892789T4 (da)	1996-04-12	2010-04-06	Warner Lambert Co	Irreversible inhibitorer af tyrosin kinaser
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6262088B1 (en)	1998-11-19	2001-07-17	Berlex Laboratories, Inc.	Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
DE19911366A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TR200102505T2 (tr)	1999-02-27	2003-01-21	Boehringer Ingelheim Pharma Kg	4-amino-kinazolin ve kinolin türevleri.
DE19911509A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SK287010B6 (sk)	1999-06-21	2009-09-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
US6627634B2 (en)	2000-04-08	2003-09-30	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US20030158196A1 (en)	2002-02-16	2003-08-21	Boehringer Ingelheim Pharma Gmbh Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
DE10063435A1 (de)	2000-12-20	2002-07-04	Boehringer Ingelheim Pharma	Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de)	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US20030225079A1 (en)	2002-05-11	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es)	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
PL1948180T3 (pl)	2005-11-11	2013-09-30	Boehringer Ingelheim Int	Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
WO2007054550A1 (en)	2005-11-11	2007-05-18	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
CA2639936C (en)	2006-01-26	2014-06-17	Boehringer Ingelheim International Gmbh	Process for preparing aminocrotonylamino-substituted quinazoline derivatives
BRPI0717586A2 (pt)	2006-09-18	2013-10-29	Boehringer Ingelheim Int	Método para tratar câncer apresentando mutações do egfr
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PE20100252A1 (es)	2008-06-06	2010-04-12	Boehringer Ingelheim Int	Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
WO2010081817A1 (en)	2009-01-14	2010-07-22	Boehringer Ingelheim International Gmbh	Method for treating colorectal cancer
WO2011003853A2 (en)	2009-07-06	2011-01-13	Boehringer Ingelheim International Gmbh	Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
JP2013512882A (ja)	2009-12-07	2013-04-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
JP5808818B2 (ja)	2010-11-25	2015-11-10	ラツィオファーム・ゲーエムベーハー	アファチニブの新規塩及び多形形態
US20150232457A1 (en)	2011-10-06	2015-08-20	Ratiopharm Gmbh	Crystalline forms of afatinib di-maleate
CN104540820B (zh)	2013-07-16	2016-12-21	杭州普晒医药科技有限公司	阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
WO2016027243A1 (en)	2014-08-21	2016-02-25	Dr. Reddy’S Laboratories Limited	Novel solid state forms of afatinib dimaleate
CN104892584B (zh)	2015-05-27	2018-03-23	重庆泰濠制药有限公司	一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
CN104926800A (zh)	2015-06-26	2015-09-23	河北神威药业有限公司	一种阿法替尼二马来酸盐的结晶形式及其制备方法

2003
- 2003-10-17 DE DE10349113A patent/DE10349113A1/de not_active Withdrawn
2004
- 2004-09-15 US US10/941,116 patent/US20050085495A1/en not_active Abandoned
- 2004-10-12 NZ NZ583049A patent/NZ583049A/en unknown
- 2004-10-12 UA UAA200605327A patent/UA91006C2/ru unknown
- 2004-10-12 SI SI200432301T patent/SI2508521T2/sl unknown
- 2004-10-12 PL PL12155662.5T patent/PL2508521T5/pl unknown
- 2004-10-12 BR BRPI0415424A patent/BRPI0415424B8/pt active IP Right Grant
- 2004-10-12 ME MEP-2008-508A patent/ME00341B/me unknown
- 2004-10-12 CA CA2759063A patent/CA2759063C/en active Active
- 2004-10-12 EA EA200600604A patent/EA016624B1/ru active Protection Beyond IP Right Term
- 2004-10-12 BR BR122013033343A patent/BR122013033343B8/pt active IP Right Grant
- 2004-10-12 PT PT47659271T patent/PT1678165E/pt unknown
- 2004-10-12 PT PT121556625T patent/PT2508521E/pt unknown
- 2004-10-12 KR KR1020127003787A patent/KR101282812B1/ko active Protection Beyond IP Right Term
- 2004-10-12 PL PL04765927T patent/PL1678165T3/pl unknown
- 2004-10-12 UA UAA200810609A patent/UA91401C2/ru unknown
- 2004-10-12 HU HUE12155662A patent/HUE028254T2/en unknown
- 2004-10-12 CN CNA2008101664841A patent/CN101402631A/zh active Pending
- 2004-10-12 RS RS20130524A patent/RS60563B1/sr unknown
- 2004-10-12 WO PCT/EP2004/011378 patent/WO2005037824A2/de active Application Filing
- 2004-10-12 SG SG200800279-2A patent/SG139743A1/en unknown
- 2004-10-12 ES ES04765927.1T patent/ES2440466T3/es active Active
- 2004-10-12 RS RS20060260A patent/RS53398B/en unknown
- 2004-10-12 MX MXPA06004076A patent/MXPA06004076A/es active IP Right Grant
- 2004-10-12 EP EP12155662.5A patent/EP2508521B2/de active Active
- 2004-10-12 EP EP04765927.1A patent/EP1678165B1/de active Active
- 2004-10-12 AU AU2004281938A patent/AU2004281938B2/en active Active
- 2004-10-12 NZ NZ547154A patent/NZ547154A/en unknown
- 2004-10-12 ES ES12155662T patent/ES2563211T5/es active Active
- 2004-10-12 RS YUP-2006/0260A patent/RS20060260A/sr unknown
- 2004-10-12 CA CA2541928A patent/CA2541928C/en active Active
- 2004-10-12 JP JP2006534662A patent/JP4594317B2/ja active Active
- 2004-10-12 KR KR1020067009605A patent/KR101180752B1/ko active Protection Beyond IP Right Term
- 2004-10-12 SI SI200432099T patent/SI1678165T1/sl unknown
- 2004-10-12 DK DK04765927.1T patent/DK1678165T3/da active
- 2004-10-12 CN CN2004800305555A patent/CN1867564B/zh active Active
- 2004-10-12 HR HRP20160246TT patent/HRP20160246T4/hr unknown
- 2004-10-12 MX MX2011004537A patent/MX338920B/es unknown
- 2004-10-12 DK DK12155662.5T patent/DK2508521T4/da active
- 2004-10-14 MY MYPI2010002645A patent/MY155425A/en unknown
- 2004-10-14 MY MYPI20044237A patent/MY149921A/en unknown
- 2004-10-14 UY UY28559A patent/UY28559A1/es active IP Right Grant
- 2004-10-15 PE PE2004001000A patent/PE20050965A1/es active IP Right Grant
- 2004-10-15 AR ARP040103754A patent/AR046118A1/es not_active Application Discontinuation
- 2004-10-15 TW TW093131395A patent/TWI348468B/zh active
- 2004-10-15 PE PE2010000135A patent/PE20100267A1/es not_active Application Discontinuation
- 2004-10-15 TW TW099147116A patent/TWI373470B/zh active
2006
- 2006-03-16 ZA ZA200602234A patent/ZA200602234B/en unknown
- 2006-04-11 IL IL174951A patent/IL174951A/en active IP Right Grant
- 2006-04-17 EC EC2006006509A patent/ECSP066509A/es unknown
- 2006-05-15 NO NO20062181A patent/NO333971B1/no unknown
- 2006-07-14 US US11/457,622 patent/US8426586B2/en active Active
2007
- 2007-03-19 HK HK07102938.4A patent/HK1095817A1/xx unknown
2010
- 2010-06-21 JP JP2010140697A patent/JP5264830B2/ja active Active
2011
- 2011-03-16 AU AU2011201171A patent/AU2011201171B2/en active Active
- 2011-11-10 IL IL216249A patent/IL216249A/en active IP Right Grant
2013
- 2013-05-10 NO NO20130663A patent/NO335103B1/no unknown
- 2013-12-09 CY CY20131101112T patent/CY1114866T1/el unknown
- 2013-12-20 HR HRP20131214TT patent/HRP20131214T1/hr unknown
2015
- 2015-02-04 UY UY0001035979A patent/UY35979A/es active IP Right Grant
2016
- 2016-03-11 CY CY20161100212T patent/CY1117279T1/el unknown

Also Published As

Publication number	Publication date
HRP20160246T4 (hr)	2022-11-11
RS53398B (en)	2014-10-31
BR122013033343B1 (pt)	2020-10-13
EP2508521B2 (de)	2022-09-07
WO2005037824A2 (de)	2005-04-28
PL1678165T3 (pl)	2014-03-31
UY28559A1 (es)	2005-05-31
SI2508521T2 (sl)	2022-11-30
DK2508521T3 (en)	2016-03-29
TW201118086A (en)	2011-06-01
PE20050965A1 (es)	2005-12-19
IL174951A (en)	2012-03-29
ES2563211T5 (es)	2022-12-27
PT1678165E (pt)	2013-11-07
KR101282812B1 (ko)	2013-07-05
KR20120037987A (ko)	2012-04-20
ME00341B (me)	2011-05-10
BR122013033343B8 (pt)	2021-05-25
ZA200602234B (en)	2007-09-26
BRPI0415424B1 (pt)	2019-01-22
AU2011201171A1 (en)	2011-04-07
IL216249A (en)	2015-05-31
RS20060260A (en)	2008-06-05
JP5264830B2 (ja)	2013-08-14
RS20130524A2 (en)	2014-06-30
UA91401C2 (en)	2010-07-26
HRP20160246T1 (hr)	2016-04-08
AR046118A1 (es)	2005-11-23
BRPI0415424A (pt)	2006-12-05
BRPI0415424B8 (pt)	2021-05-25
NZ547154A (en)	2010-02-26
AU2004281938B2 (en)	2011-04-14
SI1678165T1 (sl)	2013-12-31
ES2563211T3 (es)	2016-03-11
CY1114866T1 (el)	2016-12-14
EP1678165B1 (de)	2013-09-25
JP2007510624A (ja)	2007-04-26
US20050085495A1 (en)	2005-04-21
NO20130663L (no)	2006-05-15
EP2508521B1 (de)	2015-12-30
TWI348468B (en)	2011-09-11
PL2508521T5 (pl)	2023-03-27
EA200600604A1 (ru)	2006-10-27
RS20130524A3 (en)	2015-08-31
RS60563B1 (sr)	2020-08-31
MXPA06004076A (es)	2006-06-27
TWI373470B (en)	2012-10-01
ES2440466T3 (es)	2014-01-29
MY149921A (en)	2013-10-31
HK1095817A1 (en)	2007-05-18
UY35979A (es)	2016-09-30
KR20060120121A (ko)	2006-11-24
DE10349113A1 (de)	2005-05-12
DK2508521T4 (da)	2022-10-03
US8426586B2 (en)	2013-04-23
PE20100267A1 (es)	2010-04-21
TW200526644A (en)	2005-08-16
KR101180752B1 (ko)	2012-09-10
CA2759063A1 (en)	2005-04-28
CN1867564B (zh)	2011-06-08
JP4594317B2 (ja)	2010-12-08
MEP50808A (en)	2011-02-10
SG139743A1 (en)	2008-02-29
CA2541928A1 (en)	2005-04-28
NO333971B1 (no)	2013-11-04
WO2005037824A3 (de)	2005-07-21
ECSP066509A (es)	2006-10-10
SI2508521T1 (sl)	2016-03-31
CY1117279T1 (el)	2017-04-26
CN101402631A (zh)	2009-04-08
CN1867564A (zh)	2006-11-22
HRP20131214T1 (hr)	2014-01-31
EP1678165A2 (de)	2006-07-12
EA016624B1 (ru)	2012-06-29
EP2508521A2 (de)	2012-10-10
CA2759063C (en)	2012-04-17
HUE028254T2 (en)	2016-12-28
DK1678165T3 (da)	2013-12-09
US20070027170A1 (en)	2007-02-01
MX338920B (es)	2016-05-06
AU2004281938A1 (en)	2005-04-28
JP2010202668A (ja)	2010-09-16
UA91006C2 (ru)	2010-06-25
IL216249A0 (en)	2011-12-29
NO20062181L (no)	2006-05-15
AU2011201171B2 (en)	2012-02-09
NZ583049A (en)	2011-08-26
PL2508521T3 (pl)	2016-06-30
CA2541928C (en)	2012-12-11
NO335103B1 (no)	2014-09-15
IL174951A0 (en)	2006-08-20
EP2508521A3 (de)	2013-01-23
MY155425A (en)	2015-10-15

Publication	Publication Date	Title
PL2508521T5 (pl)	2023-03-27	Dimaleinian związku aminokrotonylowego oraz sposób jego wytwarzania
ZA200407942B (en)	2006-05-31	Methods of including terminal differentiation
EP1745573A4 (en)	2010-05-26	PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
EP1597590A4 (en)	2011-02-16	PLANNING METHOD
AU2003295410A8 (en)	2004-06-03	Piston and method of manufacture
EP1577280A4 (en)	2006-08-23	DEUTERATION PROCESS
EP1630207A4 (en)	2009-09-02	WHITE POWDER AND PROCESS FOR PRODUCING THE SAME
GB2385049B (en)	2005-10-26	Method of manufacturing powder
GB0310634D0 (en)	2003-06-11	Method of connecting components
PL365358A1 (en)	2004-08-23	Method for two-stage manufacture of di-nitrotoluene
GB0302572D0 (en)	2003-03-12	Method of treatment
GB0414061D0 (en)	2004-07-28	Method of calibrating reductant injection
GB0304555D0 (en)	2003-04-02	Compounds and methods of manufacture
EP1686990A4 (en)	2009-06-03	2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS: METHODS OF PREPARATION AND USE
EP1676578A4 (en)	2012-03-21	METHOD FOR STABILIZING DIARYLVINYLENE COMPOUND
AU2003276825A8 (en)	2004-01-23	Method of immunotherapy
AU2003299623A8 (en)	2004-08-10	Method of making mercaptoalkylalkyldialkoxysilanes
GB0305689D0 (en)	2003-04-16	Method of manufacturing and aligning an etalon
GB0219671D0 (en)	2002-10-02	Method of manufacture
GB0200049D0 (en)	2002-02-20	Method of manufacture
PL357986A1 (en)	2004-06-28	Method of manufacture of carbosteel
GB0306843D0 (en)	2003-04-30	Method of deubiquitination
PL362261A1 (en)	2005-03-21	Method for manufacture of tri-halogen-methylo-arylsulphones
PL359045A1 (en)	2004-09-20	Method for manufacture of amlodipne benzenosulphonate
PL362957A1 (en)	2005-05-02	Method for manufacture of bio-membranes